Navigation Links
Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
Date:9/20/2013

SEATTLE, Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the NewsMakers in the Biotech Industry 2013 Conference in New York City next week.  The presentation is scheduled for Friday, September 27, 2013 at 2:00 p.m. EDT.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Contact:
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
360.668.3701
jennifer@cwcomm.org


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
2. Omeros Reports Additional Positive Results from OMS824 Program
3. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
4. Omeros to Present at the Stifel Healthcare Conference 2013
5. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
6. Omeros Corporation Reports Second Quarter 2013 Financial Results
7. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
8. Omeros Submits New Drug Application to U.S. FDA for OMS302
9. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
10. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
11. Omeros Corporation Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
Breaking Medicine Technology:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... practice partnerships through affiliations and de novo development, today announced Cumberland Skin ... , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s ... Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the ... began in 2006, Melbourne has consistently come in the top three of the index. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
Breaking Medicine News(10 mins):